BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, March 11, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

June 8, 2007

View Archived Issues

Novel therapeutic agents for thrombotic and other blood coagulation disorders reported in patents

Read More

Heat shock protein 70 gene therapy safe, effective in phase I cancer study

Read More

Favorable endometrial profile seen with bazedoxifene in postmenopausal women

Read More

Progress on gene therapies reported

Read More

THCV begins phase I for obesity and metabolic disorders

Read More

Eurand and GSK reach milestone in orally disintegrating tablet collaboration

Read More

Sunesis earns milestone on progress of novel LFA-1 inhibitor candidate

Read More

MAGE-A3 cancer immunotherapeutic begins phase III study in NSCLC

Read More

Novel analgesic agents imparted in recent patent literature

Read More

New treatment options for neurological disorders reported in recent patent literature

Read More

Phase III enrollment stopped for SECTA therapy on DMC advice

Read More

Further development of XTL-2125 suspended

Read More

Interim RECORD data support Avandia safety; FDA requests more prominent product labeling

Read More

M-0002 begins phase IIa study in ascites

Read More

SLx-4090 studied in new phase IIa for dyslipidemia

Read More

Modulation of purinergic P2X and P2X2/3 receptors, a new strategy for treating urinary incontinence

Read More

Indigo inlicenses drug for treatment of arteriosclerosis obliterans

Read More

Amgen to acquire Alantos

Read More

CYT-107 to begin phase I/IIa trials in hepatitis C and oncology

Read More

Oral laquinimod to begin phase III program in relapsing MS

Read More

PF-562271 associated with activity and manageable toxicity in ongoing phase I trial

Read More

Tapestry's third-generation taxane TPI-287 advances through the pipeline

Read More

Targeted chemotherapeutic EC-145 advances to phase II clinical trials

Read More

Ongoing phase I clinical trials evaluating different dose schedules of E-7974

Read More

Antisense p53 production inhibitor improves efficacy and tolerability of cytarabine/idarubicin

Read More

Actemra significantly improves signs and symptoms of rheumatoid arthritis

Read More

AN-2728 shows comparable efficacy to betamethasone and tacrolimus in psoriasis

Read More

Japanese priority review for Taxotere in hormone refractory prostate cancer

Read More

E.U. approval for Humira for severe Crohn's disease

Read More

Remicade approved in E.U. for pediatric Crohn's disease

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 10, 2026.
  • Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

    Cas and effect: Merck’s phase III ripples HIF-2α space

    BioWorld
    Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
  • Tanycytes in green capturing tau protein in red.

    Brain’s hidden tau-clearing pathway uncovered

    BioWorld Science
    Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 10, 2026
  • MSD synthesizes α-synuclein PET agents

    BioWorld Science
    Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing